Cerevel Therapeutics, LLC   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Boston MA United States (2018)
Status: Acquired by AbbVie (2023)

Organization Overview

First Clinical Trial
2019
NCT04136873
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cerevel Therapeutics, LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Panic Disorder (Phase 1)

Parkinson Disease (Phase 3)

Schizophrenia (Phase 2)

Seizures (Phase 2)

Substance-Related Disorders (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 34
  • # of Trial APIs: 14